OneSource Specialty Pharma Limited, the demerged entity of Strides Pharma Science Limited, has received final listing and trading approval from both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) on Wednesday, January 22nd, 2025. This comes after the successful completion of a demerger process and fundraise. Strides Pharma shareholders received one share of OneSource for every two shares held in Strides. OneSource is positioned as India’s first specialty pharmaceutical contract development and manufacturing organization (CDMO). The company focuses on regulated markets and has secured significant investment from marquee investors, reflecting confidence in its growth prospects.
Key Insights:
- Demerger and Listing: The listing of OneSource unlocks value for Strides Pharma shareholders, providing them with direct ownership in a focused specialty pharma CDMO. This allows investors to specifically target their investment in the CDMO sector.
- Strategic Focus: OneSource aims to capitalize on the growing demand for specialty drug development and manufacturing services. Its focus on regulated markets suggests a strategy aimed at higher-value projects and partnerships.
- Strong Investor Backing: The successful fundraise from marquee investors indicates confidence in OneSource’s business model and growth potential. This could translate into accelerated growth and expansion for the company.
Investment Implications:
- Strides Pharma Shareholders: The listing of OneSource provides Strides Pharma shareholders with an opportunity to evaluate their investment in the demerged entity. They may choose to hold, buy more, or sell their OneSource shares based on their individual investment strategies and risk appetite.
- Potential for Growth: OneSource operates in a growing segment of the pharmaceutical industry. The increasing complexity of drug development and the need for specialized manufacturing capabilities bode well for CDMOs like OneSource.
- Market Volatility: As with any new listing, investors should be prepared for potential price volatility in the initial trading days. Careful consideration of market conditions and the company’s fundamentals is crucial.
Sources:
- Strides Pharma Unit Gets Investment Commitments Of Rs 801 Crore Ahead Of Planned Listing – NDTV Profit
- September 11, 2024 The National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 0 – Strides
- Strides Pharma rises 4% after NCLT nods creation of OneSource | News on Markets
